Inflammatory Bowel Disease: Combination of New & Traditional Treatments – Peter Buch

*** Proof of Product ***

Exploring the Essential Features of “Inflammatory Bowel Disease: Combination of New & Traditional Treatments – Peter Buch”

The evaluation and treatment of Inflammatory Bowel Disease (IBD) has dramatically changed in the last several years. These changes have improved the quality of life for many patients. In this session, Dr. Peter Buch will be discussing the new and traditional therapies. He will highlight the pros and cons of each category. He will discuss how to select the “best” therapy for your patient. He will also be identifying when surgery is the best option. This session is a case-based, practical, very interactive and fun format geared toward those who have some experience in treating IBD patients.

Speaker

Peter Buch, MD, AGAF, FACP
Peter Buch, MD, AGAF, FACP, is a double board-certified clinical gastroenterologist,  leading a team that treats all GI conditions. Dr. Buch sits on editorial boards for numerous professional journals and is a highly sought-after international presenter.

Dr. Buch has a passion for teaching. His style is case-based, practical, very interactive and evidence supported. Dr. Buch’s expertise has been shared with experienced clinicians and advanced-level students. He teaches at the University of Connecticut School of Medicine, the University of New England College of Osteopathic Medicine, the Frank H Netter School of Medicine/Quinnipiac University and the University of Connecticut APRN School.

Speaker Disclosures:
Financial: Dr. Peter S. Buch has employment relationships with the University of Connecticut School of Medicine, the University of New England College of Osteopathic Medicine, and the Frank H Netter, MD School of Medicine. He receives a speaking honorarium and recording royalties from PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: Dr. Peter S. Buch serves on the FDA and Patient Care Committees at the American College of Gastroenterology. He serves as an editor of peer-reviewed journals. He is a member of the International Association of Medical Science Educators, the AGA Academy of Educators, the American Gastroenterological Association (AGAF), the American College of Physicians (FACP), the Hartford County Medical Association, the American College of Gastroenterology (FACG), and the Connecticut State Medical Society.

Content Disclosure:

Dr. Buch references the use of antidepressants for Irritable Bowel Syndrome, and the controversial use of Fibrotest to evaluate patients with fatty liver disease who may have fibrosis of the liver. Dr. Buch indicates he wishes to present a fair and balanced approach to practitioners regarding such practices.

Objectives

1. Distinguish Inflammatory Bowell Disease from Irritable Bowel Syndrome.
2. Analyze the workup for Inflammatory Bowell Disease.
3. Recognize the treatment categories for Inflammatory Bowel Disease.
4. Discriminate the controversies surrounding Inflammatory Bowell Disease.

Outline

How to distinguish Inflammatory Bowel Disease (IBD) form Irritable Bowel Syndrome (IBS)

• Usefulness of “Alarm Signs”
• How to distinguish Chron’s Disease from Ulcerative Colitis
• Which one curable, which one treatable?
• Smoking
• Evaluation/prognosis
• Extra intestinal manifestations
• Goals of treatment

Medication Categories

• 5 ASAs
• Antibiotic use in Chron’s Disease
• Steroids
  • Dose
  • Risks
  • Duration
  • Tricks of taper
• Thiopurines
  • Risks/benefits
  • Monotherapy?
    • How to use TMTP testing
  • Monitoring for side effects
• Methotrexate
• Anti TNFs
  • Risks/benefits
  • Limitations
  • Comparing products
• Vedolizumab
  • Indications/risks/benefits
• Ustekinumab
  • Indications/risks/benefits
• Tofacininub
  • Indications/risks/benefits
• Ozanimod
  • Indications/risks/benefits
• Upadacitinib
  • Indications/risks/benefits
  • Risankizumab-raa
    • Indications/risks/benefits
  • Biosimlars
    • What we know so far

Unanswered questions in IBD

• What is the “best” medicine for my patient
• Genomics? And other markers
• Head to head studies mostly lacking
• Who should receive combination therapy?
  • Risks/benefits
• Should medications ever be stopped if pt doing well?

How successful is medical treatment?

• Surgical alternatives

Target Audience

• Nurses
• Nurse Practitioners
• Clinical Nurse Specialists
• Physicians
• Physician Assistants

Please see the full list of alternative group-buy courses available here: https://lunacourse.com/shop/